GlassScriptPhysician profile
Megan Mont
NPI 1164042925
$2,963.20
in general payments reported to CMS, 2019-2025
32 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $786 · 2024: $1,338 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $383.75 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $346.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $317.08 | 2023-2025 | Evenity, Repatha, Otezla |
| Radius Health, INC. | $310.00 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $280.76 | 2024-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $118.94 | 2023-2024 | Unithroid |
| Tandem Diabetes Care, INC. | $111.84 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $110.94 | 2023-2024 | Afrezza |
| Inspire Medical Systems, INC. | $81.71 | 2023 | Inspire |
| Abbvie INC. | $78.71 | 2023-2024 | |
| Exact Sciences Corporation | $76.90 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $74.77 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.70 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.82 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $56.39 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $50.91 | 2024-2025 | |
| Dexcom, INC. | $46.06 | 2023-2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $44.73 | 2024 | Tirosint, Licart, Flector |
| Ascendis Pharma Endocrinology INC | $41.26 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $39.96 | 2023-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $37.13 | 2023-2024 | Farxiga |
| Insulet Corporation | $27.65 | 2023 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $24.73 | 2024 | Crysvita |
| Madrigal Pharmaceuticals | $23.31 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $23.05 | 2023 | Isturisa, Signifor Lar |
| Horizon Therapeutics Plc | $22.17 | 2023 | Tepezza |
| Halozyme INC | $22.04 | 2023 | |
| Astellas Pharma US INC | $21.62 | 2024 | Veozah |
| Boston Scientific Corporation | $19.85 | 2024 | Watchman Flx |
| Verity Pharmaceuticals INC. | $18.31 | 2025 | Tlando |
| Antares Pharma, INC. | $15.88 | 2024 | Xyosted |
| Tolmar, INC. | $14.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.